When Mary Davis nearly died from the drug used to treat her breast cancer, she issued a challenge to her scientist husband: would he switch his research focus to the design of better cancer treatments? As a chemical engineer at the California Institute of Technology in Pasadena, Mark Davis was creating solid catalysts for use in chemical synthesis. But in 1996, after Mary's experience with the highly toxic chemotherapy drug doxorubicin - dubbed the 'red death' - he heeded her plea and went to work.
展开▼